Technical Data
B5001-60
BTLA (B and T Lymphocyte Attenuator, CD272)
|
Technical Data |
|
B5001-60 |
BTLA (B and T Lymphocyte Attenuator, CD272) |
|
|
Description: B and T Lymphocyte Attenuator (BTLA) also known as CD272, is a 70kD type I transmembrane glycoprotein of the CD28 family of T cell costimulatory molecules. BTLA functions as a coinhibitor on activated T cells and on B cells and dendritic cells. The extracellular domain (ECD) of this Ig superfamily protein contains one V-type Ig-like domain, which interacts with the herpesvirus entry mediator (HVEM/TNFSF14). The amino acid sequence of the ECD of human BTLA shares only 34% identity to that of mouse BTLA. One human BTLA variant lacking the transmembrane sequence has been reported. Applications: Suitable for use in Western Blot and Direct ELISA. Other applications not tested. Recommended Dilutions: Western Blot: 1-2ug/ml. Using a colormetric detection system, the detection limit is ~5ng/lane under non-reducing and reducing conditions. Direct ELISA: 0.5-1ug/ml. The detection limit is ~2ng/well. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. |
|
|||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||